Replies to post #3 on vTv Therapeutics Inc (VTVT)

[docoroc2]

Very low float, high institutional ownership. Alzheimer's product failed previous trials, but may have efficacy in early disease. Kind of a sleeper here, if they don't have to dilute and can generate some revenue in coming months. Soon, the message boards will inundate this stock. SHHHHH!!!!!.....

[DewDiligence]

VTVT starts phase-2 trial of TTP273 in T2D:

http://finance.yahoo.com/news/vtv-therapeutics-initiates-phase-2-120000796.html

VTVT has two distinct programs in type2 diabetes; both are expected to report phase-2 data during 2016.